Page last updated: 2024-12-05

tabun

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tabun: proposed as military nerve gas and exptl cholinesterase inhibitor; extremely poisonous; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6500
CHEMBL ID446997
SCHEMBL ID60863
MeSH IDM0054009

Synonyms (46)

Synonym
o-ethyl n,n-dimethyl phosphoramidocyanidate
tabun
brn 1769395
dimethylphosphoramidocyanidic acid, ethyl ester
dimethylaminocyanphosphorsaeureaethylester [german]
ethyl n,n-dimethylphosphoramidocyanidate
ethylester-dimethylamid kyseliny kyanfosfonove [czech]
dimethylamidoethoxyphosphoryl cyanide
t-2104
le-100
ethyl n-dimethylphosphoramidocyanidate
tl 1578
taboon a
ethyl dimethylphosphoramido cyanidate
ea 1205
ethyl dimethylamidocyanophosphate
gelan i
hsdb 6378
o-ethyl n,n-dimethylphosphoramidocyanidate
ethyl phosphorodimethylamidocyanidate
phosphoramidocyanidic acid, dimethyl-, ethyl ester
trilon 83
ccris 3421
ga (chemical warfare agent)
ethyl dimethylphosphoramidocyanidate
77-81-6
[dimethylamino(ethoxy)phosphoryl]formonitrile
CHEMBL446997 ,
AKOS006277925
unii-s45m750qsh
phosphoramidocyanidic acid, n,n-dimethyl-, ethyl ester
ethylester-dimethylamid kyseliny kyanfosfonove
s45m750qsh ,
dimethylaminocyanphosphorsaeureaethylester
ga [chemical warfare agent]
(+/-)-tabun
tabun [mi]
n,n-dimethylphosphoramidocyanidic acid ethyl ester
SCHEMBL60863
ethyl dimethylamidocyanidophosphate #
ethyl n,n-dimethylamino cyanophosphate
PJVJTCIRVMBVIA-UHFFFAOYSA-N
DTXSID80861631
Q143289
bdbm50241987
PD193237

Research Excerpts

Overview

Tabun is a warfare agent that inhibits human acetylcholinesterase (hAChE) by rapid phosphylation of the catalytic serine.

ExcerptReferenceRelevance
"Tabun is a warfare agent that inhibits human acetylcholinesterase (hAChE) by rapid phosphylation of the catalytic serine. "( Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation.
Carletti, E; Colletier, JP; Dupeux, F; Masson, P; Nachon, F; Trovaslet, M, 2010
)
2.04

Effects

ExcerptReferenceRelevance
"Tabun has been shown to form phosphylated adducts on tyrosine residues in albumin in vivo and in vitro. "( Mass spectral characterization of tabun-labeled lysine biomarkers in albumin.
Ding, J; Gao, R; Lu, X; Pei, C; Shi, E; Sun, F; Wang, H, 2017
)
2.18

Toxicity

The toxic effects from the released cyanide (CN) could be another reason for the delayed recovery after tabun. The influence of the time of administration of antidotal treatment consisting of anticholinergic drug (atropine) and newly developed oxime (K027 or K048) on its effectiveness was studied in mice.

ExcerptReferenceRelevance
" The in vivo protection provided by endogenous CaE was measured by the difference in the LD50 values of OP compounds in control rats and rats whose CaE activity had been inhibited by sc injection with 2 mg/kg of 2-(O-cresyl)-4H-1,3,2-benzodioxaphosphorin-2-oxide."( The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds.
Maxwell, DM, 1992
)
0.28
" Since tabun is a cyanophosphorus compound, the toxic effects from the released cyanide (CN) could be another reason for the delayed recovery after tabun."( Acute tabun toxicity; biochemical and histochemical consequences in brain and skeletal muscles of rat.
Dettbarn, WD; Gupta, RC; Patterson, GT, 1987
)
1.21
"Organophosphorus compounds can cause two distinct toxic effects: acute, which are the consequence of acetylcholinesterase (AChE) inhibition and delayed neuropathy being inhibited by inhibition of neuropathy target esterase (NTE) with first signs (ataxia, paralysis) appearing 7-20 days after intoxication."( [Anticholinesterase activity and delayed neurotoxic effects of tabun in hens].
Jokanović, M,
)
0.37
"Butyrylcholinesterase purified from human plasma (HuBChE) was evaluated both in vitro and in vivo in mice and rats as a single prophylactic antidote against the lethal effects of highly toxic organophosphates (OP)."( Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization.
Ashani, Y; Cohen, E; Grunwald, J; Marcus, D; Papier, Y; Raveh, L, 1993
)
0.29
"(1) The influence of the time of administration of antidotal treatment consisting of anticholinergic drug (atropine) and newly developed oxime (K027 or K048) on its effectiveness to eliminate tabun-induced lethal toxic effects was studied in mice."( The influence of the time of antidotal treatment administration on the potency of newly developed oximes to counteract acute toxic effects of tabun in mice.
Kassa, J, 2005
)
0.72
" In vivo experiments showed that the studied oximes were relatively toxic to mice; K033 was the most toxic (LD50=33."( In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity.
Calić, M; Jelić, D; Jun, D; Kovarik, Z; Kuca, K; Radić, B; Vrdoljak, AL, 2006
)
0.55
"The influence of newly developed oximes, K027 [1-(4-hydroxyiminomethylpyridinium)-3-(4-carbamoylpyridinium) propane dibromide] and K048 [1-(4-hydroxyiminomethylpyridinium)-3-(4-carbamoylpyridinium) butane dibromide], or currently used oximes (pralidoxime, obidoxime, trimedoxime, HI-6) and anticholinergic drugs (atropine, benactyzine) on the ability of antidotal treatment to eliminate tabun-induced acute toxic effects was studied in mice."( The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice.
Kassa, J, 2006
)
0.71
"Tabun (O-ethyl-N,N-dimethyl phosphoramidocyanidate) belongs to highly toxic organophosphorus compounds misused as chemical warfare agents for military as well as terroristic purposes."( A comparison of the potency of trimedoxime and other currently available oximes to reactivate tabun-inhibited acetylcholinesterase and eliminate acute toxic effects of tabun.
Cabal, J; Kassa, J; Kuca, K, 2005
)
1.99
"The potency of newly developed oximes (K074, K075) and commonly used oximes (obidoxime, trimedoxime, and HI-6) to counteract tabun or cyclosarin-induced acute toxic effects was studied in mice."( A comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, trimedoxime, HI-6) to counteract acute toxic effects of tabun and cyclosarin in mice.
Humlicek, V; Kassa, J, 2008
)
0.75
"; 80% of LD50 value) were evaluated."( A comparison of the potency of newly developed oximes (K347, K628) and currently available oximes (obidoxime, HI-6) to counteract acute neurotoxic effects of Tabun in rats.
Karasová, JZ; Kassa, J; Kuca, K; Musílek, K; Tesarová, S, 2010
)
0.56
"; 85% of LD50 value) were evaluated."( Evaluation of the potency of two novel bispyridinium oximes (K456, K458) in comparison with oxime K203 and trimedoxime to counteract tabun-induced neurotoxicity in rats.
Karasova, JZ; Kassa, J; Misik, J, 2013
)
0.59
" Recently, a chimeric PON1 mutant, IIG1, was engineered toward the hydrolysis of the toxic isomers of soman and cyclosarin with high in vitro catalytic efficiency."( Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro.
Ashani, Y; Goldsmith, M; Leader, H; Seeger, T; Sussman, JS; Tawfik, D; Thiermann, H; Wille, T; Worek, F, 2014
)
0.4
" Intraperitoneal administration of K048 in rats resulted in an LD50 of 238."( In vivo evaluation of cholinesterase activity, oxidative stress markers, cyto- and genotoxicity of K048 oxime–a promising antidote against organophosphate poisoning.
Kopjar, N; Kuca, K; Lucić Vrdoljak, A; Musilek, K; Zeljezić, D; Zunec, S, 2014
)
0.4
"; 90% of LD50 value) were evaluated."( The Evaluation of the Potency of Newly Developed Oximes (K727, K733) and Trimedoxime to Counteract Acute Neurotoxic Effects of Tabun in Rats.
Hatlapatková, J; Kassa, J; Žďárová Karasová, J, 2015
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of methoxime combined with a) atropine, b) benactyzine, c) atropine and natrium thiosulphate, d) atropine and diazepam on antidotal treatment effectiveness was studied in tabun-poisoned mice."( Effect of methoxime combined with anticholinergic, anticonvulsant or anti-HCN drugs in tabun-poisoned mice.
Sevelová, L; Vachek, J, 2003
)
0.73

Bioavailability

ExcerptReferenceRelevance
"From the presented data, it seems that the concept of uncharged reactivators will have to be modified, at least to improve the bioavailability and to satisfy requirements for in vivo administration."( In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?
Box, K; Ceckova, M; Dolezal, R; Gorecki, L; Hepnarova, V; Hrabinova, M; Jankockova, J; Jost, P; Jun, D; Kobrlova, T; Korabecny, J; Kuca, K; Malinak, D; Musilek, K; Nepovimova, E; Nguyen, TD; Outhwaite, B; Pavek, P; Pham, NL; Psotka, M; Sorf, A; Soukup, O, 2018
)
0.48

Dosage Studied

The achieved results have shown that oxime HI-6, so effective against soman, another nerve agent, is not the most advantageous reactivator of acetylcholinesterase for the therapy of acute tabun poisonings. In vivo, a quarter of the LD50 K203 dose insured survival of all mice after the application of as many as 8 LD50 doses of tabun.

ExcerptRelevanceReference
" Partial protection was seen in three out of three birds dosed prior to DFP challenge with sufficient C(-)P(+) isomer of soman (1."( High doses of soman protect against organophosphorus-induced delayed polyneuropathy but tabun does not.
Benschop, HP; De Bisschop, HC; Johnson, MK; Read, DJ; Willems, JL, 1988
)
0.5
" The achieved results have shown that oxime HI-6, so effective against soman, another nerve agent, is not the most advantageous reactivator of acetylcholinesterase for the therapy of acute tabun poisonings, though its efficacy is partly eliminated by its possible higher dosing in human medicine due to its lower toxicity for mammals."( [Effect of acetylcholinesterase reactivator dosage on its effectiveness in the treatment of tabun poisoning in mice].
Kassa, J, 2004
)
0.73
" In vivo, a quarter of the LD50 K203 dose insured survival of all mice after the application of as many as 8 LD50 doses of tabun, which is the highest dosage obtained compared to K048 and TMB-4."( Evaluation of oxime k203 as antidote in tabun poisoning.
Berend, S; Katalinić, M; Kovarik, Z; Kuc, K; Musilek, K; Radić, B; Vrdoljak, AL, 2009
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)Kd24.50000.00801.77505.3000AID1466195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1466205Inhibition of AChE in human erythrocyte assessed as ratio of k2/I using acetylthiocholine as substrate after 5 secs to 30 mins
AID1466195Binding affinity to human AChE
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (304)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (17.76)18.7374
1990's33 (10.86)18.2507
2000's95 (31.25)29.6817
2010's108 (35.53)24.3611
2020's14 (4.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.24 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index126.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews17 (5.40%)6.00%
Case Studies2 (0.63%)4.05%
Observational0 (0.00%)0.25%
Other296 (93.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]